Back to Journals » Cancer Management and Research » Volume 8

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

Authors Desar I, Constantinidou A, Kaal S, Jones R, van der Graaf W

Received 1 May 2016

Accepted for publication 27 June 2016

Published 17 August 2016 Volume 2016:8 Pages 95—104

DOI https://doi.org/10.2147/CMAR.S86746

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Kenan Onel


Ingrid M E Desar,1 Anastasia Constantinidou,2 Suzanne E J Kaal,1 Robin L Jones,2 Winette T A van der Graaf,1,2

1Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; 2The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK

Abstract: Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.

Keywords: soft-tissue sarcoma, trabectedin, chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]